Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain

Open access

Published version of a preprint

Abstract

Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the effects of PME to those of PSIL on the head twitch response (HTR), neuroplasticity-related synaptic proteins and frontal cortex metabolomic profiles in male C57Bl/6j mice. HTR measurement showed similar effects of PSIL and PME over 20 min. Brain specimens (frontal cortex, hippocampus, amygdala, striatum) were assayed for the synaptic proteins, GAP43, PSD95, synaptophysin and SV2A, using western blots. These proteins may serve as indicators of synaptic plasticity. Three days after treatment, there was minimal increase in synaptic proteins. After 11 days, PSIL and PME significantly increased GAP43 in the frontal cortex ( p = 0.019; p = 0.039 respectively) and hippocampus ( p = 0.015; p = 0.027) and synaptophysin in the hippocampus ( p = 0.041; p = 0.05) and amygdala ( p = 0.035; p = 0.004). PSIL increased SV2A in the amygdala ( p = 0.036) and PME did so in the hippocampus ( p = 0.014). In the striatum, synaptophysin was increased by PME only ( p = 0.023). There were no significant effects of PSIL or PME on PSD95 in any brain area when these were analyzed separately. Nested analysis of variance (ANOVA) showed a significant increase in each of the 4 proteins over all brain areas for PME versus vehicle control, while significant PSIL effects were observed only in the hippocampus and amygdala and were limited to PSD95 and SV2A. Metabolomic analyses of the pre-frontal cortex were performed by untargeted polar metabolomics utilizing capillary electrophoresis – Fourier transform mass spectrometry (CE-FTMS) and showed a differential metabolic separation between PME and vehicle groups. The purines guanosine, hypoxanthine and inosine, associated with oxidative stress and energy production pathways, showed a progressive decline from VEH to PSIL to PME. In conclusion, our synaptic protein findings suggest that PME has a more potent and prolonged effect on synaptic plasticity than PSIL. Our metabolomics data support a gradient of effects from inert vehicle via chemical psilocybin to PME further supporting differential effects. Further studies are needed to confirm and extend these findings and to identify the molecules that may be responsible for the enhanced effects of PME as compared to psilocybin alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-024-02477-w

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Induction of HTR by PSIL and PME at a psilocybin concentration of 4.4 mg/kg. a Time course of the HTR induction by each treatment separated by 2 min time bins. Both treatments induced a peak effect at 4 min post injection. b Cumulative HTR during 20 min. c The peak HTR effect induced in a 2 min time bin. n = 10–16. Compared to vehicle ****p < 0.0001. Error bars represent SEM.
Fig. 1 Induction of HTR by PSIL and PME at a psilocybin concentration of 4.4 mg/kg. a Time course of the HTR induction by each treatment separated by 2 min time bins. Both treatments induced a peak effect at 4 min post injection. b Cumulative HTR during 20 min. c The peak HTR effect induced in a 2 min time bin. n = 10–16. Compared to vehicle ****p < 0.0001. Error bars represent SEM.CC BY · PubMed Central
Fig. 2 GAP43 levels 11 days after treatment. GAP43 levels 11 days post treatment with VEH, PSIL, or PME in the brain regions of (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 17–19). One-way ANOVA (a) F (2, 51) = 4.250 p = 0.0196, (b) F (2, 54) = 1.715 p = 0.1897, (c) F (2, 55) = 4.745 p = 0.0126, (d) F (2, 54) = 2.832 p = 0.0676; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05. Error bars represent SEM.
Fig. 2 GAP43 levels 11 days after treatment. GAP43 levels 11 days post treatment with VEH, PSIL, or PME in the brain regions of (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 17–19). One-way ANOVA (a) F (2, 51) = 4.250 p = 0.0196, (b) F (2, 54) = 1.715 p = 0.1897, (c) F (2, 55) = 4.745 p = 0.0126, (d) F (2, 54) = 2.832 p = 0.0676; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05. Error bars represent SEM.CC BY · PubMed Central
Fig. 3 PSD95 levels 11 days after treatment. PSD95 levels 11 days post treatment with VEH, PSIL, or PME in the (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 19–20). One-way ANOVA (a) F (2, 54) = 0.9885 p = 0.3788 (b) F (2, 54) = 2.046 p = 0.1392, (c) F (2, 55) = 1.084 p = 0.3452, (d) F (2, 54) = 2.341 p = 0.1059; Dunnett’s multiple comparisons post hoc test. Error bars represent SEM.
Fig. 3 PSD95 levels 11 days after treatment. PSD95 levels 11 days post treatment with VEH, PSIL, or PME in the (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 19–20). One-way ANOVA (a) F (2, 54) = 0.9885 p = 0.3788 (b) F (2, 54) = 2.046 p = 0.1392, (c) F (2, 55) = 1.084 p = 0.3452, (d) F (2, 54) = 2.341 p = 0.1059; Dunnett’s multiple comparisons post hoc test. Error bars represent SEM.CC BY · PubMed Central
Fig. 4 Synaptophysin levels 11 days after treatment. Synaptophysin levels 11 days post treatment in (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 18–19). One-way ANOVA (a) F (2, 52) = 0.9234 p = 0.4036, (b) F (2, 52) = 5.549 p = 0.0065, (c) F (2, 53) = 3.842 p = 0.0277, (d) F (2, 53) = 4.653 p = 0.0138; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05, **p < 0.01. Error bars represent SEM.
Fig. 4 Synaptophysin levels 11 days after treatment. Synaptophysin levels 11 days post treatment in (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 18–19). One-way ANOVA (a) F (2, 52) = 0.9234 p = 0.4036, (b) F (2, 52) = 5.549 p = 0.0065, (c) F (2, 53) = 3.842 p = 0.0277, (d) F (2, 53) = 4.653 p = 0.0138; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05, **p < 0.01. Error bars represent SEM.CC BY · PubMed Central
Fig. 5 SV2A levels 11 days after treatment. SV2A levels 11 days post treatment with VEH, PSIL, or PME SV2A in (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 10). One-way ANOVA (a) F (2, 27) = 1.844 p = 0.1775, (b) F (2, 24) = 3.255 p = 0.0561, (c) F (2, 27) = 4.298 p = 0.024, (d) F (2, 26) = 0.02239, p = 0.9779; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05. Error bars represent SEM.
Fig. 5 SV2A levels 11 days after treatment. SV2A levels 11 days post treatment with VEH, PSIL, or PME SV2A in (a) Frontal Cortex, (b) Amygdala, (c) Hippocampus, (d) Striatum (n = 10). One-way ANOVA (a) F (2, 27) = 1.844 p = 0.1775, (b) F (2, 24) = 3.255 p = 0.0561, (c) F (2, 27) = 4.298 p = 0.024, (d) F (2, 26) = 0.02239, p = 0.9779; Dunnett’s multiple comparisons post hoc test: Compared to VEH, *p < 0.05. Error bars represent SEM.CC BY · PubMed Central
Fig. 6 Nested ANOVA of synaptic proteins. Nested ANOVA which compares the overall effect of PSIL, PME and VEH on each synaptic protein separately over all 4 brain areas: (a) GAP43 F (2, 223) = 6.354 p = 0.0021, (b) PSD 95 F (2, 55) = 4.599 p = 0.0142, (c) Synaptophysin F (2, 56) = 8.563 p = 0.0006, (d) SV2A F (2, 113) = 4.21 p = 0.0172. Compared to VEH, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 6 Nested ANOVA of synaptic proteins. Nested ANOVA which compares the overall effect of PSIL, PME and VEH on each synaptic protein separately over all 4 brain areas: (a) GAP43 F (2, 223) = 6.354 p = 0.0021, (b) PSD 95 F (2, 55) = 4.599 p = 0.0142, (c) Synaptophysin F (2, 56) = 8.563 p = 0.0006, (d) SV2A F (2, 113) = 4.21 p = 0.0172. Compared to VEH, *p < 0.05, **p < 0.01, ***p < 0.001.CC BY · PubMed Central
Fig. 7 Metabolonic Profiles. a PLS-DA plot of the metabolomic profiles of PME (red), which is clearly separated from VEH (blue) and PSIL (green) with partial overlap with both PME and VEH. b Variable importance in projection (VIP) scores (>2) - quantifying the contribution of each variable enabling the discrimination between PME, PSIL and VEH groups. Highest VIP scores (VIP > 4.0) were found for 3-Phenyllactic acid, Cystine and Phosphoenolpyruvic acid (PEP). c Heatmap of the top 25 differentially expressed metabolites across experimental groups identified by one-way ANOVA (p < 0.05). Gradual decreases in metabolite expression levels are visualized moving from vehicle control (right, blue) to psilocybin (PSIL, middle, green) to psychedelic mushroom extract (PME, left, red) groups.
Fig. 7 Metabolonic Profiles. a PLS-DA plot of the metabolomic profiles of PME (red), which is clearly separated from VEH (blue) and PSIL (green) with partial overlap with both PME and VEH. b Variable importance in projection (VIP) scores (>2) - quantifying the contribution of each variable enabling the discrimination between PME, PSIL and VEH groups. Highest VIP scores (VIP > 4.0) were found for 3-Phenyllactic acid, Cystine and Phosphoenolpyruvic acid (PEP). c Heatmap of the top 25 differentially expressed metabolites across experimental groups identified by one-way ANOVA (p < 0.05). Gradual decreases in metabolite expression levels are visualized moving from vehicle control (right, blue) to psilocybin (PSIL, middle, green) to psychedelic mushroom extract (PME, left, red) groups.CC BY · PubMed Central
Fig. 8 A heatmap visualizing specific pathway analysis of PME and VEH. The significant pathways (FDR < 0.05) and metabolites associated with them are depicted in colored squares: purine metabolism (orange), pyrimidine metabolism (green) and arginine and proline metabolism (yellow).
Fig. 8 A heatmap visualizing specific pathway analysis of PME and VEH. The significant pathways (FDR < 0.05) and metabolites associated with them are depicted in colored squares: purine metabolism (orange), pyrimidine metabolism (green) and arginine and proline metabolism (yellow).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 40

Metadata

Authors
Shahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., Wolf, G., Lotan, A., Lerer, L., Lerer, B., & Lifschytz, T.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Israel Institute for Biological Research (IL)
Corresponding author
  • Lerer, Bernard
  • Lifschytz, Tzuri
Venue
Molecular Psychiatry
Published
2024-02-20
Volume
29
Issue
7
Pages
2059-2073
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4391970820
Cited by
40
References
80
Citations by year
2026: 16 · 2025: 16 · 2024: 8
FWCI
19.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Back of the Yards algae sciences (BYAS) and Parow Entheobiosiences
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
psilocybin, tryptamine alkaloids, head-twitch response, synaptic plasticity, synaptic proteins, GAP-43, PSD-95, synaptophysin, SV2A, purine metabolism, purine nucleotides, neuroplasticity, mouse brain, hippocampus, amygdala
MeSH terms
Agaricales, Animals, Brain, Frontal Lobe, Hallucinogens, Male, Mice, Inbred C57BL, Neuronal Plasticity, Psilocybin, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. https://app.cochat.ai/papers/10.1038/s41380-024-02477-w
The paper
Shahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., Wolf, G., Lotan, A., Lerer, L., Lerer, B., & Lifschytz, T. (2024). Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Molecular Psychiatry. https://doi.org/10.1038/s41380-024-02477-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.